It’s no secret that medical research and health care have already benefited pretty significantly from the technologies and analytic techniques that comprise big data, and two new partnerships underscore the promise.
One is a five-year research partnership between the Berg pharmaceutical company and the Icahn School of Medicine at Mount Sinai, which is focused on using data to derive new therapies for cancer, as well as central nervous system and endocrine disorders. The other is a $2 million grant from the National Institutes of Health to IBM, Sutter Health and Geisinger Health System to study how electronic health records can help predict heart failure.
The Berg-Mount Sinai partnership is particularly interesting because of its scope. It’s focused on analyzing so-called “multi-omic” biology, which means the study of various systems and fields, including genomics, proteomics and metabolomics. According to Icahn professor Eric Schadt, in the press release announcing the partnership…
View original post 316 more words